Portfolio Managers Andy Acker and Agustin Mohedas explain why shares of companies delivering next-generation therapies for inflammation and immunology (I&I) disorders could have plenty of room to run.
Ironstone Asset Management named investment adviser
Developments in healthcare provision and technology
Enthusiasm can sometimes get the better of all of us. Investors always find ways to justify prices for companies at any stage in the cycle, writes William Heathcoat-Amory, partner at Kepler Trust Intelligence.